UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1160-13
Program Prior Authorization/Notification
Medication Orkambi® (lumacaftor/ivacaftor)
P&T Approval Date 5/2015, 7/2016, 11/2016, 11/2017, 9/2018, 9/2019, 9/2020, 9/2021,
9/2022, 10/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Orkambi is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane
conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in
patients aged 1 years and older who are homozygous for the F508del mutation in the CFTR
gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to
detect the presence of the F508del mutation on both alleles of the CFTR gene.1
Limitations of Use:
The efficacy and safety of Orkambi have not been established in patients with CF other than
those homozygous for the F508del mutation.1
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. Orkambi will be approved based upon all of the following criteria:
a. Diagnosis of cystic fibrosis (CF)
-AND-
b. Documentation confirming the patient is homozygous for the F508del mutation in the
CFTR gene.
-AND-
c. The patient is ≥ 1 years of age
Authorization will be issued for 12 months.
B. Reauthorization
1. Orkambi will be approved based on the following criterion:
a. Documentation of positive clinical response to Orkambi therapy (e.g., improved lung
function, stable lung function)
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Medical Necessity may be in place.
4. References:
1. Orkambi [Package Insert]. Cambridge, MA: Vertex Pharmaceuticals, Inc.; December 2024.
Program Prior Authorization/Notification - Orkambi®(lumacaftor/ivacaftor)
Change Control
5/2015 New Program
7/2016 Annual Review. Updated reference.
11/2016 Program updated modifying age restriction as label updated for
pediatric use in patients age 6 and older. Updated reference.
11/2017 Annual Review. No changes.
9/2018 Program updated modifying age restriction as label updated for
pediatric use in patients age 2 and older.
9/2019 Annual review with no changes to clinical coverage criteria.
9/2020 Annual review with no changes to clinical coverage criteria.
9/2021 Annual review. Reauthorization updated from 24 months to 12 months.
9/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote.
10/2022 Updated background and criteria with expanded indication in patients
aged 1 to 2 years. Updated reference.
6/2023 Simplified reauthorization criteria. Updated reference.
6/2024 Annual review. Increased initial authorization approval duration to 12
months. Updated reference.
6/2025 Annual review. No changes to coverage criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2